(Q37610295)

21 August 2017

title

Use of acetylcholinesterase inhibitors in Alzheimer's disease (English)

1 reference

21 August 2017

0 references

S Moghul

1

1 reference

21 August 2017

D Wilkinson

series ordinal

2

1 reference

21 August 2017

publication date

1 September 2001

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

21 August 2017

published in

1 reference

21 August 2017

volume

1

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

61-69

1 reference

Selective loss of central cholinergic neurons in Alzheimer's disease

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

Drugs for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease*

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.1.1.61

21 January 2018

Identifiers

DOI

10.1586/14737175.1.1.61

1 reference

21 August 2017

1 reference